<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01060293</url>
  </required_header>
  <id_info>
    <org_study_id>3975</org_study_id>
    <nct_id>NCT01060293</nct_id>
  </id_info>
  <brief_title>Dopamine in Acute Decompensated Heart Failure II</brief_title>
  <acronym>DAD-HF II</acronym>
  <official_title>Comparison of High-dose Furosemide, Low-dose Furosemide, and the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larissa University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larissa University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of 1) high-dose furosemide, 2) low-dose
      furosemide, and 3) low-dose furosemide combined with low-dose dopamine on diuresis, clinical
      status, renal function, electrolyte balance, length of stay, and 60-day post-discharge
      outcomes in patients hospitalized with acute decompensated heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to compare the effects of:

        1. high-dose furosemide (HDF, 40 mg furosemide bolus IV, followed by continuous IV infusion
           of 20 mg/h for a total of 8 hours),

        2. low-dose furosemide (LDF, 40 mg furosemide bolus IV, followed by continuous IV infusion
           of 5 mg/h furosemide for a total of 8 hours), and

        3. low-dose furosemide combined with low-dose dopamine (LDFD, 40 mg furosemide bolus IV,
           followed by continuous IV infusion of 5 mg/h furosemide plus 5μg/kg/min dopamine for a
           total of 8 hours) on diuresis, perceived dyspnea, renal function, electrolyte balance,
           total length of stay, and 60-day post-discharge outcomes in patients hospitalized with
           ADHF.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Safety issues in the LDFD-group (higher heart rate with dopamine)
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).</measure>
    <time_frame>60-day post discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Novel indices of acute renal ischemia/injury (cystatin-C, KIM-1, NGAL)</measure>
    <time_frame>Throughout hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">161</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>High-dose furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-dose furosemide combined with low-dose dopamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose furosemide</intervention_name>
    <description>High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours</description>
    <arm_group_label>High-dose furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose furosemide</intervention_name>
    <description>Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide</description>
    <arm_group_label>Low-dose furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low-dose furosemide combined with low-dose dopamine</intervention_name>
    <description>Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours</description>
    <arm_group_label>Low-dose furosemide combined with low-dose dopamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with New York Heart Association (NYHA) functional class IV heart failure
             according to the American Heart Association (AHA) classification, namely dyspnea on
             minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea,

          -  signs of congestion (third heart sound or pulmonary rales on physical examination),

          -  pulmonary congestion on chest x-ray,

          -  serum B-type natriuretic peptide levels &gt; 400 pg/ml or NT-proBNP &gt; 1500 pg/ml,

          -  echocardiographic documentation of systolic or diastolic dysfunction,

          -  age &gt;18 years old,

          -  on medical therapy with an ACE-inhibitor and/or a β-blocker,

          -  experiencing an acute decompensation of known chronic HF,

          -  baseline oxygen saturation &lt;90% on admission arterial blood gas

        Exclusion Criteria:

          -  acute de novo HF;

          -  severe renal failure (serum creatinine &gt;200 μmol/L or GFR &lt;30 ml/min/1.73m2)

          -  admission systolic blood pressure &lt;90 mm Hg;

          -  severe valvular disease;

          -  known adverse reactions to furosemide or dopamine;

          -  HF secondary to congenital heart disease;

          -  a scheduled procedure with a need for IV contrast dye;

          -  a scheduled cardiac surgery within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Giamouzis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Larissa University Hospital, Larissa, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filippos Triposkiadis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiology, Larissa University Hospital, Larissa, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Division of Cardiology, Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Department of Cardiology, University of Athens</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Volos General Hospital</name>
      <address>
        <city>Volos</city>
        <state>Magnesia</state>
        <zip>382 21</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Larissa University Hospital</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2010</study_first_submitted>
  <study_first_submitted_qc>February 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2010</study_first_posted>
  <last_update_submitted>September 10, 2013</last_update_submitted>
  <last_update_submitted_qc>September 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Larissa University Hospital</investigator_affiliation>
    <investigator_full_name>Gregory Giamouzis</investigator_full_name>
    <investigator_title>Assistant Professor of Cardiology</investigator_title>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Furosemide</keyword>
  <keyword>Worsening Renal Function</keyword>
  <keyword>Hypokalemia</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

